Inflammation Research

, Volume 48, Issue 10, pp 516-523

Anti-T cell strategies in asthma

  • O. M. KonAffiliated withDepartment of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London, SW3 6LY, UK, Fax +441713763138, e-mail: a.b.kay@ic.ac.uk
  • , A. B. KayAffiliated withDepartment of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London, SW3 6LY, UK, Fax +441713763138, e-mail: a.b.kay@ic.ac.uk

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract.

Chronic asthma is characterised by inflammation of the airways. Although corticosteroids are effective therapy, the risk benefit ratio is unacceptable in a minority of patients requiring chronic and high dose corticosteroid therapy because of adverse effects. There is accumulating circumstantial evidence that the CD4+ T-cell plays a central role in the pathogenesis of chronic asthma. Therapeutic strategies directed specifically at this cell type may offer a novel approach. Controlled clinical trials of cyclosporin A were effective in both chronic asthma and in a model of provoked asthma. Other immunomodulators such as FK506, rapamycin and mycophenolic acid may be useful given their modes of action on the T lymphocyte. The use of monoclonal antibody therapy directed towards these cells and T-cell peptide specific immunotherapy have been evaluated in preliminary studies and demonstrated promising results. Strategies targeting T cell co-stimulatory molecules and T-cell derived cytokines may be of therapeutic utility.

Key words: CD4+ T cells — Chronic asthma — Anti T cell antibodies — T cell peptides — Immunomodulators